Anti-TfR IgG3-Av: A New Drug Against Multiple Myeloma

抗 TfR IgG3-Av:一种抗多发性骨髓瘤的新药

基本信息

  • 批准号:
    7321093
  • 负责人:
  • 金额:
    $ 30.03万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2004
  • 资助国家:
    美国
  • 起止时间:
    2004-12-20 至 2009-11-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): We have developed an antibody fusion protein composed of avidin fused to a human IgG3 specific for the transferrin receptor (TfR). Our initial goal was to use this molecule (anti-TfR IgG3-Av) as a universal vector to deliver biotinylated agents into cancer cells. We have found that anti-TfR IgG3-Av effectively delivers biotinylated molecules into cancer cells by receptor mediated endocytosis and that these molecules remain active after their internalization. Furthermore, we have unexpectedly discovered that anti-TfR IgG3-Av, but not a recombinant anti-TfR IgG3 or a non-specific IgG3-Av, possesses a strong intrinsic antiproliferative/pro-apoptotic activity against hematopoietic malignant cell lines. Importantly, this cytotoxic activity may be further enhanced by the addition of biotinylated compounds. We now hypothesize that anti-TfR IgG3-Av can be used alone or in combination with other agents as a novel drug against an incurable plasma cell malignancy: multiple myeloma (MM). We propose to determine the effect of anti-TfR IgG3-Av on both proliferation and apoptosis of selected human MM cell lines and to define the mechanism responsible for the inhibition of proliferation and induction of apoptosis. We will also examine the additive/synergistic effect of combining anti-TfR IgG3-Av with other cytotoxic/sensitizing agents, such as biotinylated Pseudomonas exotoxin A (PE) and drugs currently used in the treatment of MM such as Thalidomide and Dexamethasone. Based on our findings we will test the efficacy of anti-TfR IgG3-Av alone or combined with other anti-cancer drugs against primary myeloma cells obtained from MM patients and against human MM tumors growing in immunodeficient mice. Thus, the proposed experiments will result in a better understanding of the mechanism of action of anti-TfR IgG3-Av and will indicate if this novel therapeutic has potential for use in the treatment of MM. We anticipate that the utility of this therapeutic will not be restricted to the elimination of myeloma cells in vivo but can also be used for in vitro approaches including the efficient purging of myeloma cells during ex vivo expansion of hematopoietic progenitor-cells for use in autologous transplantation in MM patients. We would like to stress that the impact of the results obtained from the present studies is not restricted to MM. Similar approaches can be applied to other hematopoietic malignancies such as leukemias and lymphomas.
描述(由申请人提供):我们开发了一种抗体融合蛋白,由亲和素与人类转铁蛋白受体(TfR)特异性IgG3融合而成。我们最初的目标是使用这种分子(抗tfr IgG3-Av)作为一种通用载体,将生物素化的药物输送到癌细胞中。我们发现抗tfr IgG3-Av通过受体介导的内吞作用有效地将生物素化分子传递到癌细胞中,并且这些分子在内化后仍保持活性。此外,我们意外地发现抗tfr IgG3- av,而不是重组抗tfr IgG3或非特异性IgG3- av,对造血恶性细胞系具有很强的内在抗增殖/促凋亡活性。重要的是,这种细胞毒活性可以通过添加生物素化化合物进一步增强。我们现在假设抗tfr IgG3-Av可以单独使用或与其他药物联合使用,作为一种治疗无法治愈的浆细胞恶性肿瘤:多发性骨髓瘤(MM)的新药。我们拟确定抗tfr IgG3-Av对人MM细胞系增殖和凋亡的影响,并确定其抑制增殖和诱导凋亡的机制。我们还将研究加性/协同效应

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MANUEL L PENICHET其他文献

MANUEL L PENICHET的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MANUEL L PENICHET', 18)}}的其他基金

(PQC3) Immunological Basis of Health Disparities in Multiple Myeloma
(PQC3) 多发性骨髓瘤健康差异的免疫学基础
  • 批准号:
    9054822
  • 财政年份:
    2015
  • 资助金额:
    $ 30.03万
  • 项目类别:
(PQC3) Immunological Basis of Health Disparities in Multiple Myeloma
(PQC3) 多发性骨髓瘤健康差异的免疫学基础
  • 批准号:
    8870884
  • 财政年份:
    2015
  • 资助金额:
    $ 30.03万
  • 项目类别:
A Novel Anti-HER2/neu IgE for Breast Cancer Therapy
用于乳腺癌治疗的新型抗 HER2/neu IgE
  • 批准号:
    9331321
  • 财政年份:
    2014
  • 资助金额:
    $ 30.03万
  • 项目类别:
A Novel Anti-HER2/neu IgE for Breast Cancer Therapy
用于乳腺癌治疗的新型抗 HER2/neu IgE
  • 批准号:
    8915101
  • 财政年份:
    2014
  • 资助金额:
    $ 30.03万
  • 项目类别:
A Novel Anti-HER2/neu IgE for Breast Cancer Therapy
用于乳腺癌治疗的新型抗 HER2/neu IgE
  • 批准号:
    8759266
  • 财政年份:
    2014
  • 资助金额:
    $ 30.03万
  • 项目类别:
A Novel Anti-HER2/neu IgE for Breast Cancer Therapy
用于乳腺癌治疗的新型抗 HER2/neu IgE
  • 批准号:
    9114545
  • 财政年份:
    2014
  • 资助金额:
    $ 30.03万
  • 项目类别:
Development of an anti-PSA IgE to treat prostate cancer
开发抗 PSA IgE 来治疗前列腺癌
  • 批准号:
    7608973
  • 财政年份:
    2009
  • 资助金额:
    $ 30.03万
  • 项目类别:
Anti-TfR IgG3-Av: A New Drug Against Multiple Myeloma
抗 TfR IgG3-Av:一种抗多发性骨髓瘤的新药
  • 批准号:
    7615306
  • 财政年份:
    2004
  • 资助金额:
    $ 30.03万
  • 项目类别:
Anti-TfR IgG3-Av: A New Drug Against Multiple Myeloma
抗 TfR IgG3-Av:一种抗多发性骨髓瘤的新药
  • 批准号:
    6999287
  • 财政年份:
    2004
  • 资助金额:
    $ 30.03万
  • 项目类别:
Anti-TfR IgG3-Av: A New Drug Against Multiple Myeloma
抗 TfR IgG3-Av:一种抗多发性骨髓瘤的新药
  • 批准号:
    7243585
  • 财政年份:
    2004
  • 资助金额:
    $ 30.03万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 30.03万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 30.03万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 30.03万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30.03万
  • 项目类别:
    Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 30.03万
  • 项目类别:
    Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 30.03万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 30.03万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
  • 批准号:
    10639161
  • 财政年份:
    2023
  • 资助金额:
    $ 30.03万
  • 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
  • 批准号:
    10752441
  • 财政年份:
    2023
  • 资助金额:
    $ 30.03万
  • 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
  • 批准号:
    10867639
  • 财政年份:
    2023
  • 资助金额:
    $ 30.03万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了